H. Tumbrink

发表

Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.

J. Hengstler, C. Schultz-Fademrecht, D. Rauh, 2017, Journal of medicinal chemistry.

MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer

A. Letai, Roman K. Thomas, L. Byers, 2019, Nature Communications.

CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization

K. Shokat, Roman K. Thomas, M. Peifer, 2022, Molecular cancer therapeutics.

Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors.

M. Sos, P. Nussbaumer, B. Klebl, 2022, Journal of medicinal chemistry.

Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors.

E. Stoelben, J. Wolf, R. Riedel, 2022, European journal of cancer.

Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.

S. Laufer, D. Rauh, Jonas Lategahn, 2017, Journal of medicinal chemistry.

Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S† †Electronic supplementary information (ESI) available. CCDC 1876852. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c9sc03445e

J. Hengstler, R. Zahedi, L. Kollipara, 2019, Chemical science.

Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes

Roman K. Thomas, M. Sos, Filippo Beleggia, 2020, Nature Communications.

Targeting Her2-insYVMA with Covalent Inhibitors - A Focused Compound Screening and Structure-Based Design Approach.

W. V. van Otterlo, D. Rauh, S. Bauer, 2020, Journal of medicinal chemistry.

Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

E. Smit, E. Felip, W. Engel-Riedel, 2018, Nature Communications.

The next tier of EGFR resistance mutations in lung cancer

M. Sos, Alena Heimsoeth, H. Tumbrink, 2020, Oncogene.

Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer

Roman K. Thomas, D. Planchard, M. Peifer, 2021, npj Precision Oncology.

Insights into the Kinetics of the Resistance Formation of Bacteria against Ciprofloxacin Poly(2-methyl-2-oxazoline) Conjugates.

J. Volmer, D. Rauh, Jonas Lategahn, 2018, Bioconjugate chemistry.

Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor.

C. Schultz-Fademrecht, D. Rauh, S. Bauer, 2017, Journal of medicinal chemistry.

FP14.04 Resistance to MET Inhibition in MET Driven NSCLC and Response after Switching from Type I to Type II MET Inhibitors

R. Riedel, M. Sos, J. Wolf, 2021 .

Acquired resistance to MET inhibition in MET driven NSCLC.

M. Sos, J. Wolf, R. Büttner, 2019, Journal of Clinical Oncology.